$VTYX
Ventyx Biosciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017397 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.952M $5.722M $5.338M
YoY Change 165.48% 136.25%
% of Gross Profit
Research & Development $25.47M $14.68M $17.41M
YoY Change 141.52% 54.31% -29.23%
% of Gross Profit
Depreciation & Amortization $32.00K $24.00K $21.00K
YoY Change 255.56% 380.0% 2000.0%
% of Gross Profit
Operating Expenses $31.42M $20.40M $22.75M
YoY Change 145.72% 82.35% -10.26%
Operating Profit -$31.42M -$20.40M -$22.75M
YoY Change 145.72% 82.35% -10.26%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $958.0K $380.0K $15.00K
YoY Change 7269.23% -108.69% -100.12%
Pretax Income -$30.46M -$20.02M -$22.73M
YoY Change 138.47% -62.38%
Income Tax
% Of Pretax Income
Net Earnings -$30.46M -$20.02M -$22.73M
YoY Change 138.47% 28.66% -39.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.59 -$0.39 -$0.45
Diluted Earnings Per Share -$0.59 -$0.39 -$449.4K
COMMON SHARES
Basic Shares Outstanding 50.92M 50.85M 50.73M
Diluted Shares Outstanding 51.67M 50.85M 50.59M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $412.4M $250.5M $254.3M
YoY Change 190.54% 143.66%
Cash & Equivalents $263.3M $45.34M $41.69M
Short-Term Investments $149.2M $205.1M $212.7M
Other Short-Term Assets $5.967M $1.741M $3.159M
YoY Change 663.04% -22.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $418.4M $252.2M $257.5M
YoY Change 187.24% 140.12%
LONG-TERM ASSETS
Property, Plant & Equipment $354.0K $287.0K $275.0K
YoY Change 61.64% 298.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $7.900M $18.80M
YoY Change
Other Assets $72.00K $72.00K $60.00K
YoY Change -97.46% -91.18%
Total Long-Term Assets $2.055M $9.992M $20.45M
YoY Change -32.62% 1025.23%
TOTAL ASSETS
Total Short-Term Assets $418.4M $252.2M $257.5M
Total Long-Term Assets $2.055M $9.992M $20.45M
Total Assets $420.4M $262.2M $278.0M
YoY Change 182.73% 147.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.58M $5.805M $7.114M
YoY Change 335.89% 144.63%
Accrued Expenses $16.68M $11.48M $10.40M
YoY Change 121.1% 101.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.66M $17.67M $17.79M
YoY Change 201.98% 119.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.251M $1.359M $1.039M
YoY Change
Total Long-Term Liabilities $1.251M $1.359M $1.039M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $35.66M $17.67M $17.79M
Total Long-Term Liabilities $1.251M $1.359M $1.039M
Total Liabilities $36.91M $19.03M $18.83M
YoY Change 212.58% 136.02%
SHAREHOLDERS EQUITY
Retained Earnings -$191.0M -$160.5M -$140.5M
YoY Change 90.95%
Common Stock $6.000K $5.000K $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $383.5M $243.2M $259.1M
YoY Change
Total Liabilities & Shareholders Equity $420.4M $262.2M $278.0M
YoY Change 182.73% 147.54%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$30.46M -$20.02M -$22.73M
YoY Change 138.47% 28.66% -39.61%
Depreciation, Depletion And Amortization $32.00K $24.00K $21.00K
YoY Change 255.56% 380.0% 2000.0%
Cash From Operating Activities -$23.99M -$14.79M -$12.73M
YoY Change 117.73% 14.37% 321.53%
INVESTING ACTIVITIES
Capital Expenditures -$97.00K -$28.00K $38.00K
YoY Change -52.22% 154.55%
Acquisitions
YoY Change
Other Investing Activities $64.26M $18.28M -$16.47M
YoY Change -188.07% 862.51%
Cash From Investing Activities $64.16M $18.25M -$16.50M
YoY Change -187.7% 866.63% -969.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 177.8M 249.0K 86.00K
YoY Change 252.91% -99.78% -99.85%
NET CHANGE
Cash From Operating Activities -23.99M -14.79M -12.73M
Cash From Investing Activities 64.16M 18.25M -16.50M
Cash From Financing Activities 177.8M 249.0K 86.00K
Net Change In Cash 218.0M 3.707M -29.10M
YoY Change -744.83% -96.38% -152.2%
FREE CASH FLOW
Cash From Operating Activities -$23.99M -$14.79M -$12.73M
Capital Expenditures -$97.00K -$28.00K $38.00K
Free Cash Flow -$23.89M -$14.76M -$12.76M
YoY Change 120.92% 14.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001851194
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40928
dei Entity Registrant Name
EntityRegistrantName
Ventyx Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2996852
dei Entity Address Address Line1
EntityAddressAddressLine1
662 Encinitas Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Encinitas
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92024
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
593-4832
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VTYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50917801
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45343000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70791000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
205109000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
187785000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
220000
CY2022Q2 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
39000
CY2021Q4 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
29000
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1741000
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4444000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
252193000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
263020000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
287000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
254000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1733000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
7900000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
28148000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
72000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
60000
CY2022Q2 us-gaap Assets
Assets
262185000
CY2021Q4 us-gaap Assets
Assets
291482000
CY2022Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
77000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5805000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4661000
CY2022Q2 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
74000
CY2021Q4 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
175000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11483000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7622000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
386000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17674000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12283000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1359000
CY2022Q2 us-gaap Liabilities
Liabilities
19033000
CY2021Q4 us-gaap Liabilities
Liabilities
12283000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50959950
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50526702
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50899066
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50408830
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
404987000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
397051000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1291000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160549000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117799000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
243152000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
116000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5722000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
262185000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
291482000
CY2022Q2 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
230000
CY2021Q2 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
254000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
433000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
462000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14676000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9511000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32085000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34112000
CY2022Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2021Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1675000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11060000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2422000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
20398000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
11186000
us-gaap Operating Expenses
OperatingExpenses
43145000
us-gaap Operating Expenses
OperatingExpenses
36534000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20398000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11186000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43145000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36534000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
380000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
395000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
99000
vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-11051000
CY2021Q2 vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-4329000
vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-5476000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
380000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4373000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
395000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16670000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15559000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
us-gaap Net Income Loss
NetIncomeLoss
-53204000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1552000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20018000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15559000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42750000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54756000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15559000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
us-gaap Net Income Loss
NetIncomeLoss
-53204000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-279000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1221000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-54000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20351000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15573000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43983000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53216000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.31
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.69
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50848391
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50848391
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3609462
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3609462
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50717548
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50717548
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3095244
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3095244
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
259123000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
134000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4131000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-279000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-54000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
243152000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-63662000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3058000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
288000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15559000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-75864000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
us-gaap Net Income Loss
NetIncomeLoss
-53204000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-75864000
us-gaap Profit Loss
ProfitLoss
-42750000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
26000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7575000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1221000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
243152000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-30654000
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1735000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2820000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3058000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
368000
us-gaap Profit Loss
ProfitLoss
-53204000
us-gaap Depreciation
Depreciation
45000
us-gaap Depreciation
Depreciation
5000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
148000
us-gaap Share Based Compensation
ShareBasedCompensation
7575000
us-gaap Share Based Compensation
ShareBasedCompensation
368000
vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-109000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
99000
vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-11051000
vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-5476000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21781000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2677000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1737000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-136000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
77000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-421000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1171000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
171000
vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
-101000
vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
265000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3861000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3068000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27518000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12922000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-1899000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
125397000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
127210000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1747000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1888000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
113415000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
115000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
450000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
335000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113590000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25448000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
102544000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70791000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45343000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102788000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
38911000
us-gaap Stock Issued1
StockIssued1
21345000
vtyx Deferred Offering Costs Unpaid
DeferredOfferingCostsUnpaid
453000
vtyx Unrealized Gain Loss On Marketable Securities Available For Sale Non Cash
UnrealizedGainLossOnMarketableSecuritiesAvailableForSaleNonCash
-1221000
vtyx Number Of Acquired Wholly Owned Subsidiaries
NumberOfAcquiredWhollyOwnedSubsidiaries
2
CY2022Q2 vtyx Fair Value Liabilities Level1 To Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2ToLevel3TransfersAmount
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
214298000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1289000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Significant estimates include, but are not limited to, estimates related to clinical trial prepaids and accruals, estimates related to prepaid and accrued research and development costs, available-for-sale marketable securities, estimates related to the measurement of operating lease right-of-use assets and operating lease liabilities, and determinations of the fair value of stock-based awards. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2022Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2022-01-01
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1400000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1400000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
213009000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
216002000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
86000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215933000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
26
CY2022Q2 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6756000
CY2021Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3893000
CY2022Q2 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2853000
CY2021Q4 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1025000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1800000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2529000
CY2022Q2 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
74000
CY2021Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
175000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11483000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7622000
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
21700000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
1899000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
599000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
16000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
7000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
802000
CY2021Q1 vtyx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
1576000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
143000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
143000
CY2021Q1 vtyx Business Combination Fair Value Of Shares Issued
BusinessCombinationFairValueOfSharesIssued
21032000
CY2021Q1 vtyx Business Combination Transaction Fees
BusinessCombinationTransactionFees
577000
CY2021Q1 vtyx Business Combination Fair Value Of Vested Common Stock Options Exchanged
BusinessCombinationFairValueOfVestedCommonStockOptionsExchanged
228000
CY2021Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
21837000
CY2021Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
21694000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of outstanding shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10623375
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
The leases contain various termination options.
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
vtyx Right Of Use Asset Obtained In Exchange For Operating Lease Liabilitiesin Connection With Adoption Of New Lease Standard
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilitiesinConnectionWithAdoptionOfNewLeaseStandard
1384000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
508000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1733000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
386000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1359000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1745000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
261000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
530000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
516000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
502000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
255000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2064000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
319000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1745000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
386000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1359000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4131000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
288000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7575000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
368000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6010490
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.83
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M7D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
78630000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2472855
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
417332
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
666048
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.97
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7399965
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y7D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30296000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7399965
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y7D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
30296000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1807268
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y11M15D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15018000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8157816
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33896505
CY2022Q2 vtyx Number Of Employees Terminated
NumberOfEmployeesTerminated
2
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15559000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
us-gaap Net Income Loss
NetIncomeLoss
-53204000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1552000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20018000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15559000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42750000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54756000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50848391
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50848391
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3609462
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3609462
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50717548
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50717548
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3095244
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3095244
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.31
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.69

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-017397-index-headers.html Edgar Link pending
0000950170-22-017397-index.html Edgar Link pending
0000950170-22-017397.txt Edgar Link pending
0000950170-22-017397-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtyx-20220630.htm Edgar Link pending
vtyx-20220630.xsd Edgar Link pending
vtyx-ex10_1.htm Edgar Link pending
vtyx-ex31_1.htm Edgar Link pending
vtyx-ex31_2.htm Edgar Link pending
vtyx-ex32_1.htm Edgar Link pending
vtyx-ex32_2.htm Edgar Link pending
vtyx-20220630_def.xml Edgar Link unprocessable
vtyx-20220630_lab.xml Edgar Link unprocessable
vtyx-20220630_pre.xml Edgar Link unprocessable
vtyx-20220630_htm.xml Edgar Link completed
vtyx-20220630_cal.xml Edgar Link unprocessable